Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PMN)

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

GlobeNewswire 10 days ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 

GlobeNewswire April 4, 2024

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

GlobeNewswire April 1, 2024

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

GlobeNewswire March 11, 2024

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire February 22, 2024

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

GlobeNewswire January 22, 2024

ProMIS Neurosciences Issues Letter to Shareholders

GlobeNewswire January 8, 2024

ProMIS Neurosciences, Inc. Announces Leadership Transition

GlobeNewswire January 3, 2024

ProMIS Neurosciences Announces Publication on Novel Target for ALS

GlobeNewswire December 20, 2023
View More News ››

Opinion & Analysis (NDAQ:PMN)

Building a Better Covid-19 Antibody Test

Streetwise Reports May 7, 2020

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

Streetwise Reports November 7, 2019

Alzheimer’s Solution Shows Promise after Big Pharma’s Cure Fails

Stockhouse Editorial March 28, 2019

Biotech Releases White Paper on Alzheimer's Disease Candidate

Streetwise Reports August 2, 2018

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

Streetwise Reports July 11, 2018

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase

Streetwise Reports June 28, 2018
View More Opinion ››

Bullboard Posts (NDAQ:PMN)

RE:Phase 1A

Yeah but 1b is where efficacy starts so until then it might as well be homeopathy. 
M101 - 23 hours ago

Phase 1A

If they do a cheap financing before positive results from the 1A study then the entire board is negligent and self centered. Look at...
goldtech - 1 day ago

Smells

Smells like another manipulated financing in the works. They never get this right and always do cheap financings , rather than reporting...
goldtech - 1 day ago

RE:Manipulation

Even the doubters must see by now the manipulation taking place here.  I mean, last week there was a stready climb to around $2.50...
BottomBroker - 2 days ago

RE:Manipulation

If they didn't want the bump on investor show wouldn't they just have kept Gail?   
M101 - 3 days ago

Manipulation

Wow someone is playing games and wants a lot of cheap shares, guess who?
goldtech - 3 days ago
View more Bullboard ››

Silver Tiger Metals Inc

Silver Tiger Metals Inc

Silver Tiger Metals Inc. is a Canada-based company, which is engaged in exploring and developing the historic EL Tigre Mine ...
View More »